Prescription of anti-osteoporosis drugs during 2004-2007-a nationwide register study in Norway

European Journal of Clinical Pharmacology

Volumn 66, Issue 3, 2010, Pages 299-306

  Devold, Helene M ^a   Doung, Gia Man ^a   Tverdal, Aage ^a   Furu, Kari ^a   Meyer, Haakon E ^a,b   Falch, Jan A ^a   Sogaard, Anne Johanne ^a,b  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Anti osteoporosis drugs; Bisphosphonates; Minimumrefill; Norway; Osteoporosis; Prescription drug use

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; COLECALCIFEROL; ETIDRONIC ACID; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

ADULT; AGE DISTRIBUTION; AGED; AMBULATORY CARE; ARTICLE; CONTROLLED STUDY; FEMALE; FRAGILITY FRACTURE; GEOGRAPHIC DISTRIBUTION; HUMAN; INCIDENCE; INFORMATION RETRIEVAL; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NORWAY; POPULATION RESEARCH; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; REGISTER; SEX RATIO; AGE; CLINICAL PRACTICE; DEMOGRAPHY; DRUG USE; DRUG UTILIZATION; FRACTURE; HEALTH CARE DISPARITY; MIDDLE AGED; OSTEOPOROSIS; SEX DIFFERENCE; STATISTICS; TIME;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; DRUG PRESCRIPTIONS; DRUG UTILIZATION; DRUG UTILIZATION REVIEW; FEMALE; FRACTURES, BONE; HEALTHCARE DISPARITIES; HUMANS; MALE; MIDDLE AGED; NORWAY; OSTEOPOROSIS; PHYSICIAN'S PRACTICE PATTERNS; REGISTRIES; RESIDENCE CHARACTERISTICS; SEX FACTORS; TIME FACTORS;

EID: 77951934607     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-009-0746-0     Document Type: Article

References (30)

1. Falch JA, Meyer HE (1998) Osteoporosis and fractures in Norway. Occurrence and risk factors. Tidsskr Nor Laegeforen 118:568-572
2. Lofthus CM, Osnes EK, Falch JA, Kaastad TS, Kristiansen IS, Nordsletten L, Stensvold I, Meyer HE (2001) Epidemiology of hip fractures in Oslo, Norway. Bone 29:413-418
3. Lunt M, Felsenberg D, Adams J, Benevolenskaya L, Cannata J, Dequeker J, Dodenhof C, Falch JA, Johnell O, Khaw KT,Masaryk P, Pols H, Poor G, Reid D, Scheidt-Nave C, Weber K, Silman AJ, Reeve J (1997) Population-based geographic variations inDXAbone density in Europe: the EVOS Study. European Vertebral Osteoporosis. Osteoporos Int 7:175-189
4. O'Neill TW, Felsenberg D, Varlow J, Cooper C, Kanis JA, Silman AJ (1996) The prevalence of vertebral deformity in European men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res 11:1010-1018
5. Bulajic-Kopjar M, Wiik J, Nordhagen R (1998) Regional differences in the incidence of femoral neck fractures in Norway. Tidsskr Nor Laegeforen 118:30-33
6. Falch JA, Ilebekk A, Slungaard U (1985) Epidemiology of hip fractures in Norway. Acta Orthop Scand 56:12-16
7. Falch JA, Kaastad TS, Bohler G, Espeland J, Sundsvold OJ (1993) Secular increase and geographical differences in hip fracture incidence in Norway. Bone 14:643-645
8. Omsland TK, Gjesdal CG, Emaus N, Tell GS, Meyer HE (2008) Regional differences in hip bone mineral density levels in Norway: the NOREPOS study. Osteoporos Int 20:631-638
9. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333
10. Furu K (2008) Establishment of the nationwide Norwegian Prescription Database (NorPD)-new opportunities for research in pharmacoepidemiology in Norway. Norsk Epidemiologi 18:129-136
11. Rønning M (2008) WHO Collaborating Centre for Drug Statistics methodology. Guidelines for ATC classification and DDD assignment 2008, 11 ed. WHO, Geneva
12. Rønning M (2008) Drug Consumption in Norway 2003-2007. Norwegian Institute of Public Health. Available via http://www.legemiddelforbruk.no/ english/. Accessed 15 Jul 2008
13. Norwegian Institute of Public Health (2008) The Norwegian Prescription Database. http://www.norpd.no/. Accessed 1 Nov 2008
14. Caetano PA, Lam JM, Morgan SG (2006) Toward a standard definition and measurement of persistence with drug therapy: examples from research on statin and antihypertensive utilization. Clin Ther 28:1411-1424
15. Gabrielsen B, Lillegård M, Otnes B, Abrahamsen D, Strand P (2008) Individual based statistics of care and nursing services in the community] (in Norwegian). http://www.ssb.no/emner/03/02/ notat-200842/notat-200842.pdf Accessed 15 Jan 2009
16. Beardon PH, McGilchrist MM, McKendrick AD, McDevitt DG, MacDonald TM (1993) Primary non-compliance with prescribed medication in primary care. BMJ 307:846-848
17. Kanis JA, Johnell O, De Laet C, Jonsson B, Oden A, Ogelsby AK (2002) International variations in hip fracture probabilities: implications for risk assessment. J Bone Miner Res 17:1237-1244
18. Kanis JA, Delmas P, Burckhardt P, Cooper C, Torgerson D (1997) Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. Osteoporos Int 7:390-406
19. Kanis JA, Borgstrom F, De LC, Johansson H, Johnell O, Jonsson B, Oden A, Zethraeus N, Pfleger B, Khaltaev N (2005) Assessment of fracture risk. Osteoporos Int 16:581-589
20. The National Board of Health and Welfare, Sweden (2008) [Pharmaceuticals-statistics for 2007]. http://www.socialstyrelsen.se/NR/ rdonlyres/4F805341-CF4F-4997-B770-CD181AB9EAFF/10179/2008461.pdf. Accessed 16 Feb 2009
21. Vestergaard P, Rejnmark L, Mosekilde L (2005) Osteoporosis is markedly underdiagnosed: a nationwide study from Denmark. Osteoporos Int 16:134-141
22. The Danish Medicines Agency (2009) [Annual statistics on medicinal products]. http://www.medstat.dk/. Accessed 15 Feb 2009
23. Cadarette SM, Gignac MA, Jaglal SB, Beaton DE, Hawker GA (2007) Access to osteoporosis treatment is critically linked to access to dual-energy x-ray absorptiometry testing. Med Care 45:896-901
24. Dolan AL, Koshy E, Waker M, Goble CM (2004) Access to bone densitometry increases general practitioners' prescribing for osteoporosis in steroid treated patients. Ann Rheum Dis 63:183-186
25. Norwegian Medicines Agency (2007) The stepped price model. http://www.legemiddelverket.no/upload/Dokumenter/Legemid deløkonomi/ Trinnprismodellen.eng.off.071024.pdf. Accessed 2 Jul 2008
26. Norwegian Medicines Agency (undated) [Osteoporosis and reimbursement]. http://www.legemiddelverket.no/templates/Inter Page-60535.aspx. Accessed 2 Jul 2008
27. The Norwegian Labour and Welfare administration (2006) [Control of reimbursed drugs. Report on physicians prescribing in reimbursement code 42 (established osteoporosis)]. http://www. nav.no/binary?id= 1073752918&download=true. Accessed 21 Jul 2008
28. The Norwegian Labour and Welfare administration (2008) [Controll of reimbursed drugs. Report on physicians prescribing in reimbursement code 42 (established osteoporosis)]. http://www. nav.no/binary?id= 805477010&download=true. Accessed 21 Jul 2008
29. Gallagher AM, Rietbrock S, Olson M, van Staa TP (2008) Fracture outcomes related to persistence and compliance with oral bisphosphonates. J Bone Miner Res 23:1569-1575
30. Weycker D, Macarios D, Edelsberg J, Oster G (2006) Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 17:1645-1652